Clinical Trials Logo

Immunization clinical trials

View clinical trials related to Immunization.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03943875 Active, not recruiting - Clinical trials for Human Papilloma Virus

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Start date: June 17, 2019
Phase: Phase 4
Study type: Interventional

We are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.

NCT ID: NCT03609320 Active, not recruiting - Vaccination Clinical Trials

The STOP-HPV Trial 5: Single Arm Evaluation of the Bundle

STOP_HPV
Start date: January 12, 2022
Phase: N/A
Study type: Interventional

Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates. This single-arm study (embedded within arm 2 of a 2-arm cluster randomized clinical trial (RCT)) will test the effectiveness (and cost-effectiveness) of a bundled intervention (HPV vaccine communication, performance feedback reports and provider prompts), in practices that previously received standard of care, to reduce MOs and increase HPV vaccination rates.

NCT ID: NCT03599583 Active, not recruiting - Vaccination Clinical Trials

The STOP-HPV Trial 3: Prompts Intervention

STOP-HPV
Start date: August 7, 2018
Phase: N/A
Study type: Interventional

Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates. This study is part of a series of cluster randomized clinical trials (RCTs) that will test the effectiveness (and cost-effectiveness) of the addition of prompts (period 3) to performance feedback (period 2, continued through period 3) and training providers previously received on HPV vaccine communication (period 1) to reduce MOs and increase HPV vaccination rates.